CARL STAFSTROM

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology with Special Qualifications in Child Neurology BALTIMORE, MD NPI 1912979196

General Payments — all program years on this page

$16,028.57

  • Category: General Payments
  • Program years: PY2019–2024
  • Record count: 20
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $9,863.19 across 10 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $8,943.751
Travel and Lodging $653.443
Food and Beverage $266.006

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $9,863.1910

By program year

Program yearAmountRecords
2019 $6,165.3810
2024 $9,863.1910

Records — PY2024 (10)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1137681227 Takeda Pharmaceuticals U.S.A., Inc. $346.63 03/01/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137681229 Takeda Pharmaceuticals U.S.A., Inc. $122.17 03/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137681231 Takeda Pharmaceuticals U.S.A., Inc. $22.80 03/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137681233 Takeda Pharmaceuticals U.S.A., Inc. $196.81 03/02/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137681235 Takeda Pharmaceuticals U.S.A., Inc. $38.01 03/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137681237 Takeda Pharmaceuticals U.S.A., Inc. $17.33 03/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137681239 Takeda Pharmaceuticals U.S.A., Inc. $47.44 03/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137681241 Takeda Pharmaceuticals U.S.A., Inc. $18.25 03/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137681243 Takeda Pharmaceuticals U.S.A., Inc. $110.00 04/04/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137681245 Takeda Pharmaceuticals U.S.A., Inc. $8,943.75 04/04/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.